

Zydus partners with Bioeq for US commercialisation rights for NUFYMCO®

24 December 2025 | News

Zydus will be responsible for the commercialisation of NUFYMCO® in the US market



Bioeq AG, a Swiss biopharmaceutical company, and Ahmedabad-based Zydus Lifesciences has announced that its wholly owned subsidiary, Zydus Lifesciences Global FZE, United Arab Emirates has entered into a strategic partnership with Bioeq, for the licensing, supply and commercialisation of Bioeq's Vascular Endothelial Growth Factor (VEGF) inhibitor NUFYMCO®, an interchangeable biosimilar of Lucentis® (Ranibizumab) for the US market. Lucentis® is a registered trademark of Genentech, Inc., a member of the Roche Group.

The Biologics License Application (BLA) for NUFYMCO® has been approved by US Food and Drug Administration (USFDA) on December 18, 2025. This transaction marks an expansion of Zydus' US biosimilar business, following its recent partnership with Formycon AG for a biosimilar of Keytruda® (Pembrolizumab).

Under the terms of this agreement, Bioeq will be responsible for the development, manufacturing, registration and supply of the finished product, while Zydus will be responsible for the commercialisation of NUFYMCO® in the US market.

Speaking on the development, Managing Director of Zydus Lifesciences Limited, Dr Sharvil P. Patel, said, "We are happy to collaborate with Bioeq to bring an interchangeable biosimilar to Lucentis® (Ranibizumab) in the US market. Through this partnership, we will leverage our combined expertise and resources to accelerate organisational growth while ensuring maximum value to patients through an expanded access to affordable ophthalmology care."